BAUSCH + LOMB CORP (BLCO) Stock Price & Overview
NYSE:BLCO • CA0717051076
Current stock price
The current stock price of BLCO is 16.49 USD. Today BLCO is down by -1.14%. In the past month the price decreased by -6.31%. In the past year, price increased by 36.17%.
BLCO Key Statistics
- Market Cap
- 5.855B
- P/E
- 32.98
- Fwd P/E
- 20.41
- EPS (TTM)
- 0.50
- Dividend Yield
- N/A
BLCO Stock Performance
BLCO Stock Chart
BLCO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BLCO. When comparing the yearly performance of all stocks, BLCO is one of the better performing stocks in the market, outperforming 71.94% of all stocks.
BLCO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BLCO. BLCO has a medium profitability rating, but doesn't score so well on its financial health evaluation.
BLCO Earnings
On February 18, 2026 BLCO reported an EPS of 0.32 and a revenue of 1.41B. The company missed EPS expectations (-10.76% surprise) and missed revenue expectations (-0.28% surprise).
BLCO Forecast & Estimates
19 analysts have analysed BLCO and the average price target is 18.83 USD. This implies a price increase of 14.18% is expected in the next year compared to the current price of 16.49.
For the next year, analysts expect an EPS growth of 61.57% and a revenue growth 7.01% for BLCO
BLCO Groups
Sector & Classification
BLCO Financial Highlights
Over the last trailing twelve months BLCO reported a non-GAAP Earnings per Share(EPS) of 0.5. The EPS decreased by -19.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.57% | ||
| ROE | -5.58% | ||
| Debt/Equity | 0.78 |
BLCO Ownership
BLCO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| MDLN | MEDLINE INC-CL A | 29.67 | 57.802B | ||
| COO | COOPER COS INC/THE | 14.03 | 13.937B | ||
| ALGN | ALIGN TECHNOLOGY INC | 14.83 | 12.312B | ||
| SOLV | SOLVENTUM CORP | 9.68 | 11.164B | ||
| LNTH | LANTHEUS HOLDINGS INC | 14.09 | 4.891B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 16.34 | 4.055B | ||
| ICUI | ICU MEDICAL INC | 14.9 | 3.092B | ||
| HAE | HAEMONETICS CORP/MASS | 10.57 | 2.613B | ||
| XRAY | DENTSPLY SIRONA INC | 7.93 | 2.329B | ||
| NEOG | NEOGEN CORP | 27.75 | 2.043B | ||
| UFPT | UFP TECHNOLOGIES INC | 18.84 | 1.496B | ||
| STAA | STAAR SURGICAL CO | 142.99 | 957.028M | ||
| BVS | BIOVENTUS INC - A | 11.48 | 760.823M |
Related stock screener links
View all stocks in the Health Care Supplies Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BLCO
Company Profile
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,000 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Company Info
IPO: 2022-05-06
BAUSCH + LOMB CORP
520 Applewood Crescent
Vaughan ONTARIO CA
Employees: 13500
Phone: 19082552864
BAUSCH + LOMB CORP / BLCO FAQ
What does BLCO do?
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,000 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
What is the stock price of BAUSCH + LOMB CORP today?
The current stock price of BLCO is 16.49 USD. The price decreased by -1.14% in the last trading session.
Does BLCO stock pay dividends?
BLCO does not pay a dividend.
What is the ChartMill rating of BAUSCH + LOMB CORP stock?
BLCO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is BAUSCH + LOMB CORP (BLCO) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BLCO.
Can you provide the growth outlook for BAUSCH + LOMB CORP?
The Revenue of BAUSCH + LOMB CORP (BLCO) is expected to grow by 7.01% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for BAUSCH + LOMB CORP?
BAUSCH + LOMB CORP (BLCO) has a market capitalization of 5.86B USD. This makes BLCO a Mid Cap stock.